American Kidney Fund's rating was adjusted for Joint Costs. If you are a donor who considers direct mail, telemarketing, and other Joint Cost solicitations to be true charitable programs, the below efficiency ratios, which were not adjusted for joint costs, may better reflect your goals.
| Program % | Cost to Raise $100 |
|---|---|
| 96% | $2 |
| Entity | Document Type | Tax ID |
|---|---|---|
| American Kidney Fund | Audited Financial Statements | 23-7124261 |
| American Kidney Fund | IRS Form 990 | 23-7124261 |
|
Entity: American Kidney Fund Document Type: Audited Financial Statements Tax ID: 23-7124261 |
|
Entity: American Kidney Fund Document Type: IRS Form 990 Tax ID: 23-7124261 |
| Name | Title | Compensation | |
|---|---|---|---|
| 1 | Lavarne Burton | President/CEO | $903,717 |
| 2 | Tara Bunch | EVP/COO | $534,702 |
| 3 | Marshall Strisik | VP and General Counsel | $477,627 |
|
1 Name: Lavarne Burton Title: President/CEO Compensation: $903,717 |
|
2 Name: Tara Bunch Title: EVP/COO Compensation: $534,702 |
|
3 Name: Marshall Strisik Title: VP and General Counsel Compensation: $477,627 |
According to the American Kidney Fund (AKF) audit of December 31, 2023 (Note 2, Summary of Significant Accounting Policies, Risks and Uncertainties): "...The US District Court, Central District of California granted a preliminary injunction preventing California AB 290 from becoming law on December 30, 2019. Litigation was then severely delayed due to the COVID-19 pandemic. Currently, the parties await a decision on the State of California's motion for reconsideration of Judge Carter's January 4, 2024, summary judgment ruling. That ruling granted summary judgment in part for AKF and granted summary judgment in part for the State of California. AKF's Health Insurance Premium Program was unaffected by the summary judgment decision. However, because both sides of the litigation have indicated they will likely appeal any negative decision to the 9th Circuit Court of appeals, the long-term impact on grant assistance is currently unknown..." See here for more information on California AB 290 "...In January 2023, AKF received a civil investigative subpoena from the District of Columbia Attorney General's office. The investigative subpoena called for certain documents and records related to (i) AKF's relationships with DaVita, Fresenius, and American Renal Associates in the District; and (ii) AKF's compliance with the D.C. Non-Profit Corporations Act. AKF met with District of Columbia officials in March 2023 and turned over multiple tranches of documents and records as requested. AKF has received no communication from the Attorney General's office since meeting with them in early 2023 and has no reason to believe there will be anything further on the matter." See here for more information on this topic from the The New York Times |
According to the American Kidney Fund (AKF) audit of December 31, 2023 (Note 2, Summary of Significant Accounting Policies, In-Kind Contributions): AKF received in-kind contributions during the fiscal year-ended December 31, 2023, on which it placed a total value of $951,422. Of this amount, $866,622 and $84,800 was attributed to "Advertising, Printing, and Donated Items for Patients and Events" and "Donated Services," respectively. [Note: CharityWatch generally excludes the value of in-kind (non-cash) donations of goods and services from its calculations of Program % and Cost to Raise $100. More information on how grades are calculated and the treatment of in-kind donations can be found on the Our Process page.] |
According to the American Kidney Fund (AKF) audit of December 31, 2023 (Note 11, Public Support): "...AKF received public support from two corporations in the amount of $301,094,000 and $290,943,500 during the years ended December 31, 2023 and 2022, respectively. These contributions represented 86% and 85% of the total support and revenue for the years ended December 31, 2023 and 2022, respectively." |
